1067186-56-4

Basic information

• Product Name: PSI-421
• Synonyms: PSI-421;2-(1-(4-Chlorophenyl)Cyclopropyl)-3-Hydroxy-8-(Trifluoromethyl)Quinoline-4-Carboxylic Acid;2-(1-(4-Chlorophenyl)Cyclopropyl)-3-Hydroxy-8-(Trifluoromethyl)Quinoline-4-Carboxylic Acid(WXC02524)
• CAS NO: 1067186-56-4
• Molecular Formula: C20H13ClF3NO3
• Molecular Weight: 407.7703296
• Mol File: 1067186-56-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PSI-421(CAS DataBase Reference)
• NIST Chemistry Reference: PSI-421(1067186-56-4)
• EPA Substance Registry System: PSI-421(1067186-56-4)

Safety Data

• Hazardous Substances Data: 1067186-56-4(Hazardous Substances Data)

Usage

General Description

PSI-421 is a novel chemical compound that is being developed as a potential treatment for various central nervous system disorders. It belongs to a class of drugs known as phosphodiesterase inhibitors, which work by increasing levels of cyclic adenosine monophosphate (cAMP) in the brain. This elevation of cAMP has been shown to have neuroprotective and neuroregenerative effects, making PSI-421 a promising candidate for conditions such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Early preclinical studies have demonstrated its ability to improve cognitive function and reduce neuroinflammation, suggesting that PSI-421 may offer a new approach to addressing the underlying pathology of these disorders. Further research and clinical trials are needed to fully evaluate its safety and efficacy in humans.

Upstream product

• 1067187-79-4 2-(1-(4-chlorophenyl)cyclopropyl)-2-oxoethyl acetate 
• 391-12-8 7-trifluoromethylisatin 

Relevant articles and documents

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.